Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 461

1.

Loss of FBXO7 results in a Parkinson's-like dopaminergic degeneration via an RPL23-MDM2-TP53 pathway.

Stott SRW, Randle SJ, Al Rawi S, Rowicka P, Harris R, Mason B, Xia J, Dalley JW, Barker RA, Laman H.

J Pathol. 2019 May 29. doi: 10.1002/path.5312. [Epub ahead of print]

PMID:
31144295
2.

L-dopa responsiveness in early Parkinson's disease is associated with the rate of motor progression.

Malek N, Kanavou S, Lawton MA, Pitz V, Grosset KA, Bajaj N, Barker RA, Ben-Shlomo Y, Burn DJ, Foltynie T, Hardy J, Williams NM, Wood N, Morris HR, Grosset DG; PRoBaND clinical consortium.

Parkinsonism Relat Disord. 2019 May 14. pii: S1353-8020(19)30243-3. doi: 10.1016/j.parkreldis.2019.05.022. [Epub ahead of print]

PMID:
31105012
3.

Targeting Huntingtin Expression in Patients with Huntington's Disease.

Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, Wild EJ, Saft C, Barker RA, Blair NF, Craufurd D, Priller J, Rickards H, Rosser A, Kordasiewicz HB, Czech C, Swayze EE, Norris DA, Baumann T, Gerlach I, Schobel SA, Paz E, Smith AV, Bennett CF, Lane RM.

N Engl J Med. 2019 Jun 13;380(24):2307-2316. doi: 10.1056/NEJMoa1900907. Epub 2019 May 6.

PMID:
31059641
4.

Relationship between neuromelanin and dopamine terminals within the Parkinson's nigrostriatal system.

Martín-Bastida A, Lao-Kaim NP, Roussakis AA, Searle GE, Xing Y, Gunn RN, Schwarz ST, Barker RA, Auer DP, Piccini P.

Brain. 2019 May 5. pii: awz120. doi: 10.1093/brain/awz120. [Epub ahead of print]

PMID:
31056699
5.

Parkinson disease and growth factors - is GDNF good enough?

Kirkeby A, Barker RA.

Nat Rev Neurol. 2019 Jun;15(6):312-314. doi: 10.1038/s41582-019-0180-6. No abstract available.

PMID:
30948845
6.

WNT5A is transported via lipoprotein particles in the cerebrospinal fluid to regulate hindbrain morphogenesis.

Kaiser K, Gyllborg D, Procházka J, Salašová A, Kompaníková P, Molina FL, Laguna-Goya R, Radaszkiewicz T, Harnoš J, Procházková M, Potěšil D, Barker RA, Casado ÁG, Zdráhal Z, Sedláček R, Arenas E, Villaescusa JC, Bryja V.

Nat Commun. 2019 Apr 2;10(1):1498. doi: 10.1038/s41467-019-09298-4.

7.

Assessment of the Performance of a Modified Motor Scale as Applied to Juvenile Onset Huntington's Disease.

Horton MC, Nopoulos P, Nance M, Landwehrmyer GB, Barker RA, Squitieri F; REGISTRY Investigators of the European Huntington’s Disease Network, Burgunder JM, Quarrell O.

J Huntingtons Dis. 2019;8(2):181-193. doi: 10.3233/JHD-180306.

8.

Hyperosmotic stress induces cell-dependent aggregation of α-synuclein.

Fragniere AMC, Stott SRW, Fazal SV, Andreasen M, Scott K, Barker RA.

Sci Rep. 2019 Feb 19;9(1):2288. doi: 10.1038/s41598-018-38296-7.

9.

Pathological Mechanisms and Clinical Aspects of GBA1 Mutation-Associated Parkinson’s Disease.

Stoker TB, Torsney KM, Barker RA.

In: Stoker TB, Greenland JC, editors. Parkinson’s Disease: Pathogenesis and Clinical Aspects [Internet]. Brisbane (AU): Codon Publications; 2018 Dec 21. Chapter 3.

10.

The Differential Diagnosis of Parkinson’s Disease.

Greenland JC, Barker RA.

In: Stoker TB, Greenland JC, editors. Parkinson’s Disease: Pathogenesis and Clinical Aspects [Internet]. Brisbane (AU): Codon Publications; 2018 Dec 21. Chapter 6.

11.

Disease-Modification in Huntington's Disease: Moving Away from a Single-Target Approach.

Jensen MP, Barker RA.

J Huntingtons Dis. 2019;8(1):9-22. doi: 10.3233/JHD-180320.

PMID:
30636742
12.

Ensuring safety in public playgrounds is everybody's business.

Barker RA, Eager D, Sharwood LN.

Med J Aust. 2019 Jan;210(1):9-11.e1. doi: 10.5694/mja18.00549. Epub 2018 Dec 28. No abstract available.

PMID:
30636314
13.

Platelet abnormalities in Huntington's disease.

Denis HL, Lamontagne-Proulx J, St-Amour I, Mason SL, Rowley JW, Cloutier N, Tremblay MÈ, Vincent AT, Gould PV, Chouinard S, Weyrich AS, Rondina MT, Barker RA, Boilard E, Cicchetti F.

J Neurol Neurosurg Psychiatry. 2019 Mar;90(3):272-283. doi: 10.1136/jnnp-2018-318854. Epub 2018 Dec 19.

14.

The Peripheral Inflammatory Response to Alpha-Synuclein and Endotoxin in Parkinson's Disease.

White AJ, Wijeyekoon RS, Scott KM, Gunawardana NP, Hayat S, Solim IH, McMahon HT, Barker RA, Williams-Gray CH.

Front Neurol. 2018 Nov 20;9:946. doi: 10.3389/fneur.2018.00946. eCollection 2018.

15.

Developing and validating Parkinson's disease subtypes and their motor and cognitive progression.

Lawton M, Ben-Shlomo Y, May MT, Baig F, Barber TR, Klein JC, Swallow DMA, Malek N, Grosset KA, Bajaj N, Barker RA, Williams N, Burn DJ, Foltynie T, Morris HR, Wood NW, Grosset DG, Hu MTM.

J Neurol Neurosurg Psychiatry. 2018 Dec;89(12):1279-1287. doi: 10.1136/jnnp-2018-318337. Epub 2018 Jul 25.

16.

Exploring causality of the association between smoking and Parkinson's disease.

Gallo V, Vineis P, Cancellieri M, Chiodini P, Barker RA, Brayne C, Pearce N, Vermeulen R, Panico S, Bueno-de-Mesquita B, Vanacore N, Forsgren L, Ramat S, Ardanaz E, Arriola L, Peterson J, Hansson O, Gavrila D, Sacerdote C, Sieri S, Kühn T, Katzke VA, van der Schouw YT, Kyrozis A, Masala G, Mattiello A, Perneczky R, Middleton L, Saracci R, Riboli E.

Int J Epidemiol. 2018 Nov 20. doi: 10.1093/ije/dyy230. [Epub ahead of print]

17.

iPSC Modeling of Presenilin1 Mutation in Alzheimer's Disease with Cerebellar Ataxia.

Li L, Roh JH, Chang EH, Lee Y, Lee S, Kim M, Koh W, Chang JW, Kim HJ, Nakanishi M, Barker RA, Na DL, Song J.

Exp Neurobiol. 2018 Oct;27(5):350-364. doi: 10.5607/en.2018.27.5.350. Epub 2018 Oct 31.

18.

Tackling Ethical Challenges of Premature Delivery of Stem Cell-Based Therapies: ISSCR 2018 Annual Meeting Focus Session Report.

Sugarman J, Barker RA, Kerridge I, Lysaght T, Pellegrini G, Sipp D, Tanner C.

Stem Cell Reports. 2018 Nov 13;11(5):1021-1025. doi: 10.1016/j.stemcr.2018.10.020.

19.

Portrait of blood-derived extracellular vesicles in patients with Parkinson's disease.

Lamontagne-Proulx J, St-Amour I, Labib R, Pilon J, Denis HL, Cloutier N, Roux-Dalvai F, Vincent AT, Mason SL, Williams-Gray C, Duchez AC, Droit A, Lacroix S, Dupré N, Langlois M, Chouinard S, Panisset M, Barker RA, Boilard E, Cicchetti F.

Neurobiol Dis. 2019 Apr;124:163-175. doi: 10.1016/j.nbd.2018.11.002. Epub 2018 Nov 5.

PMID:
30408591
20.

Monocyte Function in Parkinson's Disease and the Impact of Autologous Serum on Phagocytosis.

Wijeyekoon RS, Kronenberg-Versteeg D, Scott KM, Hayat S, Jones JL, Clatworthy MR, Floto RA, Barker RA, Williams-Gray CH.

Front Neurol. 2018 Oct 16;9:870. doi: 10.3389/fneur.2018.00870. eCollection 2018.

21.

Ensuring safety in public playgrounds is everybody's business.

Barker RA, Eager D, Sharwood LN.

Med J Aust. 2018 Oct 29. [Epub ahead of print] No abstract available.

PMID:
30359559
22.

Emerging Treatment Approaches for Parkinson's Disease.

Stoker TB, Torsney KM, Barker RA.

Front Neurosci. 2018 Oct 8;12:693. doi: 10.3389/fnins.2018.00693. eCollection 2018. Review.

23.

Outcome of cell suspension allografts in a patient with Huntington's disease.

Maxan A, Mason S, Saint-Pierre M, Smith E, Ho A, Harrower T, Watts C, Tai Y, Pavese N, Savage JC, Tremblay MÈ, Gould P, Rosser AE, Dunnett SB, Piccini P, Barker RA, Cicchetti F.

Ann Neurol. 2018 Dec;84(6):950-956. doi: 10.1002/ana.25354. Epub 2018 Oct 25.

24.

Multimorbidity Predicts Quality of Life but not Motor Severity in Early Parkinson's Disease.

Gravell R, Duncan GW, Khoo TK, Burn DJ, Sayer AA, Barker RA, Lawson RA, Yarnall AJ.

J Parkinsons Dis. 2018;8(4):511-515. doi: 10.3233/JPD-181428.

PMID:
30248064
25.

Platelet-derived extracellular vesicles in Huntington's disease.

Denis HL, Lamontagne-Proulx J, St-Amour I, Mason SL, Weiss A, Chouinard S, Barker RA, Boilard E, Cicchetti F.

J Neurol. 2018 Nov;265(11):2704-2712. doi: 10.1007/s00415-018-9022-5. Epub 2018 Sep 12.

PMID:
30209650
26.

Long-Term Follow-Up of a Phase I/II Study of ProSavin, a Lentiviral Vector Gene Therapy for Parkinson's Disease.

Palfi S, Gurruchaga JM, Lepetit H, Howard K, Ralph GS, Mason S, Gouello G, Domenech P, Buttery PC, Hantraye P, Tuckwell NJ, Barker RA, Mitrophanous KA.

Hum Gene Ther Clin Dev. 2018 Sep;29(3):148-155. doi: 10.1089/humc.2018.081.

27.

Huntingtin Aggregation Impairs Autophagy, Leading to Argonaute-2 Accumulation and Global MicroRNA Dysregulation.

Pircs K, Petri R, Madsen S, Brattås PL, Vuono R, Ottosson DR, St-Amour I, Hersbach BA, Matusiak-Brückner M, Lundh SH, Petersén Å, Déglon N, Hébert SS, Parmar M, Barker RA, Jakobsson J.

Cell Rep. 2018 Aug 7;24(6):1397-1406. doi: 10.1016/j.celrep.2018.07.017.

28.

The clinical heterogeneity of Parkinson's disease and its therapeutic implications.

Greenland JC, Williams-Gray CH, Barker RA.

Eur J Neurosci. 2019 Feb;49(3):328-338. doi: 10.1111/ejn.14094. Epub 2018 Oct 14.

PMID:
30059179
29.

Categorising Visual Hallucinations in Early Parkinson's Disease.

Clegg BJ, Duncan GW, Khoo TK, Barker RA, Burn DJ, Yarnall AJ, Lawson RA.

J Parkinsons Dis. 2018;8(3):447-453. doi: 10.3233/JPD-181338.

PMID:
30040741
30.

Regenerative Therapies for Parkinson's Disease: An Update.

Stoker TB, Barker RA.

BioDrugs. 2018 Aug;32(4):357-366. doi: 10.1007/s40259-018-0294-1. Review.

PMID:
30027398
31.

The motor and cognitive features of Parkinson's disease in patients with concurrent Gaucher disease over 2 years: a case series.

Collins LM, Williams-Gray CH, Morris E, Deegan P, Cox TM, Barker RA.

J Neurol. 2018 Aug;265(8):1789-1794. doi: 10.1007/s00415-018-8908-6. Epub 2018 May 29.

32.

Abnormalities of age-related T cell senescence in Parkinson's disease.

Williams-Gray CH, Wijeyekoon RS, Scott KM, Hayat S, Barker RA, Jones JL.

J Neuroinflammation. 2018 May 28;15(1):166. doi: 10.1186/s12974-018-1206-5.

33.

Author Correction: Defective Sphingosine-1-phosphate metabolism is a druggable target in Huntington's disease.

Di Pardo A, Amico E, Basit A, Armirotti A, Joshi P, Neely MD, Vuono R, Castaldo S, Digilio AF, Scalabrì F, Pepe G, Elifani F, Madonna M, Jeong SK, Park BM, D'Esposito M, Bowman AB, Barker RA, Maglione V.

Sci Rep. 2018 May 24;8(1):8266. doi: 10.1038/s41598-018-23083-1.

34.

New approaches for brain repair-from rescue to reprogramming.

Barker RA, Götz M, Parmar M.

Nature. 2018 May;557(7705):329-334. doi: 10.1038/s41586-018-0087-1. Epub 2018 May 16. Review.

PMID:
29769670
35.

The Challenges of First-in-Human Stem Cell Clinical Trials: What Does This Mean for Ethics and Institutional Review Boards?

Barker RA, Carpenter MK, Forbes S, Goldman SA, Jamieson C, Murry CE, Takahashi J, Weir G.

Stem Cell Reports. 2018 May 8;10(5):1429-1431. doi: 10.1016/j.stemcr.2018.04.010. Review.

36.

Longitudinal diffusion tensor imaging changes in early Parkinson's disease: ICICLE-PD study.

Minett T, Su L, Mak E, Williams G, Firbank M, Lawson RA, Yarnall AJ, Duncan GW, Owen AM, Khoo TK, Brooks DJ, Rowe JB, Barker RA, Burn D, O'Brien JT.

J Neurol. 2018 Jul;265(7):1528-1539. doi: 10.1007/s00415-018-8873-0. Epub 2018 Apr 25.

PMID:
29696499
37.

Dynamic and Cell-Specific DACH1 Expression in Human Neocortical and Striatal Development.

Castiglioni V, Faedo A, Onorati M, Bocchi VD, Li Z, Iennaco R, Vuono R, Bulfamante GP, Muzio L, Martino G, Sestan N, Barker RA, Cattaneo E.

Cereb Cortex. 2018 Apr 24. doi: 10.1093/cercor/bhy092. [Epub ahead of print]

PMID:
29688344
38.

Dermal fibroblasts from patients with Parkinson's disease have normal GCase activity and autophagy compared to patients with PD and GBA mutations.

Collins LM, Drouin-Ouellet J, Kuan WL, Cox T, Barker RA.

Version 2. F1000Res. 2017 Sep 26 [revised 2018 Jan 1];6:1751. doi: 10.12688/f1000research.12090.2. eCollection 2017.

39.

Simple Generation of a High Yield Culture of Induced Neurons from Human Adult Skin Fibroblasts.

Shrigley S, Pircs K, Barker RA, Parmar M, Drouin-Ouellet J.

J Vis Exp. 2018 Feb 5;(132). doi: 10.3791/56904.

40.

Predicting clinical diagnosis in Huntington's disease: An imaging polymarker.

Mason SL, Daws RE, Soreq E, Johnson EB, Scahill RI, Tabrizi SJ, Barker RA, Hampshire A.

Ann Neurol. 2018 Mar;83(3):532-543. doi: 10.1002/ana.25171. Epub 2018 Mar 13.

41.

Features of GBA-associated Parkinson's disease at presentation in the UK Tracking Parkinson's study.

Malek N, Weil RS, Bresner C, Lawton MA, Grosset KA, Tan M, Bajaj N, Barker RA, Burn DJ, Foltynie T, Hardy J, Wood NW, Ben-Shlomo Y, Williams NW, Grosset DG, Morris HR; PRoBaND clinical consortium.

J Neurol Neurosurg Psychiatry. 2018 Jul;89(7):702-709. doi: 10.1136/jnnp-2017-317348. Epub 2018 Jan 29.

42.

Using Medical Claims Analyses to Understand Interventions for Parkinson Patients.

Bloem BR, Ypinga JHL, Willis A, Canning CG, Barker RA, Munneke M, De Vries NM.

J Parkinsons Dis. 2018;8(1):45-58. doi: 10.3233/JPD-171277.

43.

Erratum: Author Correction: Using a smartphone-based self-management platform to support medication adherence and clinical consultation in Parkinson's disease.

Lakshminarayana R, Wang D, Burn D, Chaudhuri KR, Galtrey C, Guzman NV, Hellman B, James B, Pal S, Stamford J, Steiger M, Stott RW, Teo J, Barker RA, Wang E, Bloem BR, van der Eijk M, Rochester L, Williams A.

NPJ Parkinsons Dis. 2017 Nov 13;3:32. doi: 10.1038/s41531-017-0034-0. eCollection 2017.

44.

Human Trials of Stem Cell-Derived Dopamine Neurons for Parkinson's Disease: Dawn of a New Era.

Barker RA, Parmar M, Studer L, Takahashi J.

Cell Stem Cell. 2017 Nov 2;21(5):569-573. doi: 10.1016/j.stem.2017.09.014.

45.

11 C-PE2I and 18 F-Dopa PET for assessing progression rate in Parkinson's: A longitudinal study.

Li W, Lao-Kaim NP, Roussakis AA, Martín-Bastida A, Valle-Guzman N, Paul G, Loane C, Widner H, Politis M, Foltynie T, Barker RA, Piccini P.

Mov Disord. 2018 Jan;33(1):117-127. doi: 10.1002/mds.27183. Epub 2017 Oct 30.

46.

An open-label study to assess the feasibility and tolerability of rilmenidine for the treatment of Huntington's disease.

Underwood BR, Green-Thompson ZW, Pugh PJ, Lazic SE, Mason SL, Griffin J, Jones PS, Rowe JB, Rubinsztein DC, Barker RA.

J Neurol. 2017 Dec;264(12):2457-2463. doi: 10.1007/s00415-017-8647-0. Epub 2017 Oct 26.

47.

Associations between Lifestyle Factors and Parkinson's Disease in an Urban Sri Lankan Clinic Study.

Wijeyekoon R, Suriyakumara V, Gamage R, Fernando T, Jayasuriya A, Amarasinghe D, Gunasekara H, Sirisena D, Amaratunga D, Muthukuda C, Barker RA, Williams-Gray C, De Silva R.

Int Arch Med. 2017 Sep 15;10. pii: 246. doi: 10.3823/2516.

48.

Direct Neuronal Reprogramming for Disease Modeling Studies Using Patient-Derived Neurons: What Have We Learned?

Drouin-Ouellet J, Pircs K, Barker RA, Jakobsson J, Parmar M.

Front Neurosci. 2017 Sep 28;11:530. doi: 10.3389/fnins.2017.00530. eCollection 2017. Review.

49.

Spatial structure normalises working memory performance in Parkinson's disease.

Fallon SJ, Bor D, Hampshire A, Barker RA, Owen AM.

Cortex. 2017 Nov;96:73-82. doi: 10.1016/j.cortex.2017.08.023. Epub 2017 Sep 1.

PMID:
28985531
50.

Defective Sphingosine-1-phosphate metabolism is a druggable target in Huntington's disease.

Di Pardo A, Amico E, Basit A, Armirotti A, Joshi P, Neely MD, Vuono R, Castaldo S, Digilio AF, Scalabrì F, Pepe G, Elifani F, Madonna M, Jeong SK, Park BM, D'Esposito M, Bowman AB, Barker RA, Maglione V.

Sci Rep. 2017 Jul 13;7(1):5280. doi: 10.1038/s41598-017-05709-y. Erratum in: Sci Rep. 2018 May 24;8(1):8266.

Supplemental Content

Loading ...
Support Center